Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 683Carcinoma, Renal Cell 225Urinary Bladder Neoplasms 195Carcinoma, Transitional Cell 111Breast Neoplasms 96Kidney Neoplasms 89Carcinoma, Non-Small-Cell Lung 82Neoplasms 81Melanoma 78Ovarian Neoplasms 77Colorectal Neoplasms 68Neoplasm Metastasis 66Non-Muscle Invasive Bladder Neoplasms 56Lung Neoplasms 53Pancreatic Neoplasms 46Sarcoma 45Stomach Neoplasms 42Endometrial Neoplasms 41Uterine Cervical Neoplasms 39Wilms Tumor 33Adenocarcinoma 33Esophageal Neoplasms 31Carcinoma, Hepatocellular 31Squamous Cell Carcinoma of Head and Neck 30Triple Negative Breast Neoplasms 29Head and Neck Neoplasms 27Testicular Neoplasms 24Metastatic Castration-resistant Prostate Cancer 24Neuroblastoma 23Colonic Neoplasms 23

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × Genitourinary × 90 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡